Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Sung‐Sik Han

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7047-7961; OpenAlex author ID A5076832811. Sources: OpenAlex.

Their work

Papers
34 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
64
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 3 papers · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 4 papers · 2019: 5 papers · 2020: 1 paper · 2021: 2 papers · 2022: 4 papers · 2023: 2 papers · 2024: 2 papers · 2025: 4 papers · 2026: 1 paper

Papers 34

  1. Impact of treatment sequence and dose response on outcomes in locally advanced pancreatic cancer treated with hypofractionated proton beam therapy using simult… Co-author DOI 10.1016/j.radonc.2025.111295↗
  2. Increased diagnosis of hepato-biliary-pancreatic cancer after cholecystectomy: a population-based study. Co-author DOI 10.1038/s41598-024-84781-7↗
  3. Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicente… Co-author DOI 10.1093/clinchem/hvaf066↗
  4. Diagnostic Biomarker Candidates Proposed Using Targeted Lipid Metabolomics Analysis of the Plasma of Patients with PDAC. Co-author DOI 10.3390/cancers17182988↗
  5. Epidemiology and survival analysis according to the histologic subtype of pancreatic cancer: a population-based cohort study. Last author DOI 10.4174/astr.2025.108.1.20↗
  6. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. Co-author DOI 10.1111/cas.16104↗
  7. Conditional Relative Survival of Exocrine Pancreatic Cancer: A Population-Based Study. Last author DOI 10.1245/s10434-023-14594-x↗
  8. Exocrine pancreatic cancer as a second primary malignancy: A population-based study. Co-author DOI 10.14701/ahbps.23-053↗
  9. Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4143/crt.2023.291↗
  10. Comparison of oncologic outcomes between open and laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma using data from the KOTUS-BP national… Co-author DOI 10.1016/j.hpb.2022.01.012↗
  11. Korean Surgical Practice Guideline for Pancreatic Cancer 2022: A summary of evidence-based surgical approaches First author DOI 10.14701/ahbps.22-009↗
  12. Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea. Co-author DOI 10.3346/jkms.2022.37.e216↗
  13. First Course of treatment and Prognosis of Exocrine Pancreatic Cancer in Korea from 2006 to 2017. Co-author DOI 10.4143/crt.2021.421↗
  14. Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study. Co-author DOI 10.3390/cancers13215466↗
  15. Overall survival of pancreatic ductal adenocarcinoma is doubled by Aldh7a1 deletion in the KPC mouse. Co-author DOI 10.7150/thno.53935↗
  16. Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer. Co-author DOI 10.1038/s41598-020-78875-1↗
  17. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2019.06.002↗
  18. Cytopathological results of initial endoscopic ultrasound-guided fine needle aspiration for primary mass and prognosis in pancreatic cancer patients. Co-author DOI 10.1111/cyt.12675↗
  19. Surgery for elderly patients with resectable pancreatic cancer, a comparison with non-surgical treatments: a retrospective study outcomes of resectable pancrea… Co-author DOI 10.1186/s12885-019-6255-3↗
  20. Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Sam… Co-author DOI 10.3389/fonc.2019.00875↗
  21. Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuva… Co-author DOI 10.5009/gnl18355↗
  22. Favorable glycemic response after pancreatoduodenectomy in both patients with pancreatic cancer and patients with non-pancreatic cancer. Co-author DOI 10.1097/md.0000000000010590↗
  23. Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer. Co-author DOI 10.1177/1533033818783879↗
  24. Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1373/clinchem.2017.283721↗
  25. Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction c… Co-author DOI 10.3857/roj.2018.00073↗
  26. Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine fo… Co-author DOI 10.4143/crt.2016.495↗
  27. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial. Co-author DOI 10.1016/j.pan.2016.09.001↗
  28. Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1186/1748-717x-8-160↗
  29. Risk of pancreatic cancer in relation to ABO blood group and hepatitis C virus infection in Korea: a case-control study. Co-author DOI 10.3346/jkms.2013.28.2.247↗
  30. Cancer cells with p53 deletion detected by fluorescent in situ hybridization in peritoneal drainage fluid is correlated with early peritoneal seeding in resect… First author DOI 10.4174/jkss.2013.84.4.209↗
  31. Multiple primary malignant neoplasms in pancreatic cancer patients: a single-center experience in Korea. Co-author DOI 10.1097/mpa.0b013e3182374d65↗
  32. CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. First author DOI 10.1016/j.ijrobp.2010.10.011↗
  33. Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and u… Co-author DOI 10.1016/j.ijrobp.2011.02.063↗
  34. Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET. Last author DOI 10.1097/rlu.0b013e31820a9eea↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sang‐Jae Park · 29 shared papers, 2011–2025 · strength 3.54
  2. Sang Myung Woo · 23 shared papers, 2011–2026 · strength 2.33
  3. Woo Jin Lee · 20 shared papers, 2011–2026 · strength 1.97
  4. Hyeong Min Park · 8 shared papers, 2019–2025 · strength 1.80
  5. Mee Joo Kang · 7 shared papers, 2013–2025 · strength 1.47
  6. Jung Won Chun · 5 shared papers, 2023–2026 · strength 1.07
  7. Yun‐Hee Kim · 9 shared papers, 2016–2025 · strength 1.05
  8. Sun‐Young Kong · 8 shared papers, 2017–2025 · strength 0.99
  9. Kyu‐Won Jung · 3 shared papers, 2022–2025 · strength 0.76
  10. Sun‐Whe Kim · 5 shared papers, 2013–2023 · strength 0.73
  11. Min Kyeong Kim · 6 shared papers, 2017–2025 · strength 0.73
  12. Tae Hyun Kim · 12 shared papers, 2011–2020 · strength 0.71
  13. Kyong‐Ah Yoon · 6 shared papers, 2017–2024 · strength 0.61
  14. Eun Kyung Hong · 10 shared papers, 2011–2021 · strength 0.60
  15. Young‐Joo Won · 3 shared papers, 2022–2023 · strength 0.54
  16. Jin‐Hyeok Hwang · 3 shared papers, 2019–2025 · strength 0.41
  17. Soo‐Youl Kim · 2 shared papers, 2021–2025 · strength 0.35
  18. Dae Yong Kim · 6 shared papers, 2011–2020 · strength 0.34
  19. Young Ae Kim · 1 shared paper, 2025 · strength 0.30
  20. Chang Moo Kang · 2 shared papers, 2022 · strength 0.27
  21. Tae Hyun Kim · 1 shared paper, 2026 · strength 0.27
  22. Sung Yong Choi · 2 shared papers, 2019–2024 · strength 0.27
  23. Eun Sang Oh · 3 shared papers, 2018–2020 · strength 0.26
  24. Eui Joo Kim · 1 shared paper, 2025 · strength 0.22
  25. Min Kyu Jung · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.